Minimal-Change Disease

Back

Background

Minimal-change disease (MCD), also known as lipoid nephrosis or nil disease, is the most common single form of nephrotic syndrome in children. It refers to a histopathologic lesion in the glomerulus that almost always is associated with nephrotic syndrome. It typically is a disease of childhood, but it also can occur in adults.

Pathophysiology

It is postulated that MCD is a disorder of T cells, which release a cytokine that injures the glomerular epithelial foot processes. This, in turn, leads to a decreased synthesis of polyanions. The polyanions constitute the normal charge barrier to the filtration of macromolecules, such as albumin. When the polyanions are damaged, leakage of albumin follows. The identity of this circulating permeability factor is uncertain, although it is postulated that it may be hemopexin.

Some of the cytokines that have been studied in MCD are interleukin-12 (IL-12) and interleukin-4 (IL-4). IL-12 levels have been found to be elevated in peripheral blood monocytes during the active phase and normalized during remission. Interleukin-18 (IL-18) can synergize with IL-12 to selectively increase the production of vascular permeability factor from T cells. In addition, levels of IL-4 and CD23 (a receptor for immunoglobulin E [IgE][1] ) have been found to be elevated in peripheral blood lymphocytes.

Synaptopodin is a proline-rich protein intimately associated with actin microfilaments present in the foot processes of podocytes. Greater synaptopodin expression in podocytes is associated with a significantly better response to steroid therapy. On the other hand, the expression of synaptopodin does not predict progression of MCD or diffuse mesangial hypercellularity to focal segmental glomerulosclerosis (FSGS). Thus, this marker could be used in the future to help determine appropriate therapy.

Interleukin-13 (IL-13) has been implicated in the pathogenesis of MCD. In a study on Chinese children in Singapore, it was shown that IL-13 genetic polymorphisms correlate with the long-term outcome of MCD. An animal study by Lai et al suggested that IL-13 overexpression can cause podocyte foot process fusion and proteinuria.[2]

In patients who develop acute renal failure, endothelin 1 expression is greater in the glomeruli, vessels, and tubules than in the nonacute renal failure group. The glomerular epithelial cells (podocytes) and the slit diaphragm connecting the podocyte foot processes play a primary role in the development of proteinuria.

Nephrin is a major component of the slit diaphragm. The slit diaphragm is often missing in MC nephrotic syndrome (MCD) kidneys. The role of nephrin and the slit diaphragm in MCD is not known. However, genetic variants of a glomerular filter protein may play a role in some patients with MCD.

Izzedine et al found a lack of glomerular dysferlin expression associated with minimal-change nephropathy in a patient with limb-girdle muscular dystrophy type 2B.[3] In the same study, 2 of 3 other patients with dysferlinopathy had microalbuminuria.

CD 80, a protein found in B cells and responsible for T-cell activation, is found to be increased in patients with MCD. However, the levels of this protein are not elevated in the urines of patients with FSGS compared with patients with MCD. Thus, this may have clinical applicability in distinguishing these two entities.[4]

In a study of 37 patients with MCD, 27 patients with FSGS, 30 patients with other glomerulopathies, and 71 healthy controls, Ling and colleagues found that urinary CD80 concentrations were significantly higher in patients with active MCD compared with patients with FSGS or other glomerulopathies and controls. At a cutoff value of 328.98 ng/g creatinine, urinary CD80 had a sensitivity of 81.1 % and a specificity of 94.4 % for diagnosing MCD.[5]

Epidemiology

Frequency

United States

In preadolescents, minimal-change nephrotic syndrome (MCNS) makes up 85-95% of all cases of nephrotic syndrome. In adolescents and young adults, the prevalence is 50%, while in adults, MCNS accounts for 10-15% of primary nephrotic syndrome cases. The incidence of nephrotic syndrome is 2-7 new cases annually per 100,000 children, and the prevalence is 15 cases per 100,000 children.

Mortality/Morbidity

Very few patients progress to end-stage renal disease. These patients are those who have FSGS that has been misdiagnosed as MCD.

Hypovolemic shock is perhaps the most serious complication of MCD. Hypovolemic shock typically occurs during the edema-forming phase of relapse and may be precipitated by diarrhea, sepsis, drainage of ascitic fluid, or the use of diuretics.

Hypertension, somewhat paradoxically, also may occur in approximately 9-14% of children. Hypertension occurs in approximately 30% of adults, with a greater incidence in older patients (>60 y).

Thromboembolic events are serious complications of nephrotic syndrome. Peripheral thrombosis may result in gangrene, and deep venous thrombosis in the legs or pelvic veins may be a source of pulmonary emboli. Bacterial infections, especially peritonitis, occur with greater frequency, partly because of the loss of immunoglobulin G (IgG) and complement factors B and D in the urine. In fact, the largest reduction in mortality in these patients follows the introduction of antibiotics rather than any specific therapy.

Race-, Sex-, and Age-related Demographics

Rates of MCD vary as follows:

History

Facial edema is noted first. Edema may be preceded by an upper respiratory tract infection, an allergic reaction to a bee sting, the use of certain drugs, or malignancies.

Malaise and easy fatigability can occur. Weight gain often is an additional feature.

The patient also may present with one or more of the following:

Causes

Almost all cases are idiopathic, but a small percentage of cases (approximately 10-20%) may have an identifiable cause. Secondary cases may be due to any of the following:

Physical Examination

The blood pressure usually is normal in children[6] but may be elevated in adults. (In addition, the plasma creatinine in adults is often slightly elevated at presentation.)

Dependent edema is the most prominent sign. The retina has a wet appearance. Subungual edema with horizontal lines (called Muehrcke lines) also may occur.

Hernias may be found, and the elasticity of the ears may be decreased.

Heavy proteinuria over an extended period of time leads to a state of protein depletion with muscle wasting, thinning of the skin, and growth failure.

Pleural and ascitic fluid can accumulate. Rarely, cellulitis, peritonitis, or pneumonia may be the first indication of an underlying nephrotic syndrome.

Children may have growth failure.

Histologic Findings

Light microscopy

In patients with MCD, the glomerulus is, by definition, normal or nearly so when examined with the light microscope; however, the precise limits of normal are not clearly defined. This creates difficulty in differentiating the appearance of minimal change with mild mesangial proliferation from a mesangial proliferative glomerulonephritis. Diagnosis can be even more difficult because, at the peak age of onset (approximately 3 y), the mesangial and epithelial cells are more prominent. In adult patients, diagnosis is made more challenging by superimposed arterionephrosclerosis secondary to hypertension.

In children with frequently relapsing MCD, some involuted glomeruli may be present. These lesions are small and sclerotic but retain their podocyte and parietal epithelial cell constituents. The presence of these glomeruli is related to the duration of the disease.

The most common tubular lesion is protein and lipid droplets in epithelial cells due to increased reabsorption. The presence of areas of tubular atrophy and interstitial fibrosis should raise the suspicion of FSGS.

Immunohistology

These studies usually do not demonstrate significant glomerular deposition of immunoglobulins or complement components in patients with MCD. Some biopsy specimens may be positive for low-level IgM deposits not accompanied by mesangial dense deposits.

Electron microscopy

Retraction of the epithelial foot processes is observed consistently in patients with MCD. This is, at times, erroneously described as foot-process fusion and results from disordered epithelial cell structure with withdrawal of the dendritic process. This finding is not unique to MCD, and the diagnosis is one of exclusion of other diseases based on lack of other processes on light microscopy, immunohistology, or electron microscopy.

Approach Considerations

Urinalysis findings are benign in minimal-change disease (MCD), but profound proteinuria and oval fat bodies may be observed. In children, the critical level for diagnosis is proteinuria of more than 40 mg/h/m2. In adults, the threshold is more than 3.5 g/d/1.73 m2.

A random albumin-to-creatinine concentration ratio is in excess of 5. Urine specific gravity is high because of proteinuria. A 24-hour urine measurement should be obtained for protein and creatinine clearance.

Hypoalbuminemia is an important marker of nephrotic syndrome. The level at which edema occurs varies, but it tends to be lower in children than in adults. Nephrotic syndrome in children is defined by a serum albumin of less than 2.5 g/dL. Hyperlipidemia also is a feature of a nephrotic state.

Other laboratory findings are as follows:

Renal sonogram results are normal in patients with MCD.

Because MCD accounts for 90% of all cases of idiopathic nephrotic syndrome in children, renal biopsy is not part of the initial workup for MCD in that age group. Instead, biopsy is performed only in those children who fail to achieve remission with an empiric course of corticosteroids. In contrast, a renal biopsy is performed in all adult patients with nephrotic syndrome, before the initiation of treatment for MCD.

Consultations

Consultation with a nephrologist generally is needed. The nephrologist has the expertise to perform and interpret the renal biopsy. A renal pathologist has the expertise to interpret biopsy findings under light microscopy, immunofluorescence, and electron microscopy.

Approach Considerations

Because of the high prevalence of minimal-change disease (MCD) in children with nephrotic syndrome, an empiric trial of corticosteroids commonly is the first step in therapy. Corticosteroids are the treatment of choice, leading to complete remission of proteinuria in most cases. Approximately 90% of children respond within 2 weeks to prednisone at a dose of 2 mg/kg/day (not to exceed 80 mg/day). After the remission of proteinuria, prednisone is continued for another 6 weeks, at lower doses.

In some children, proteinuria fails to clear by 6-8 weeks, and performing a renal biopsy may be useful to determine if another process may be present. For example, MCD secondary to Hodgkin lymphoma is frequently resistant to steroids and will remit with cure of the primary disease. Generally, if proteinuria persists after two relapses or courses of steroids, a tissue diagnosis should be made before starting cytotoxic or immunosuppressive therapy.

Adults respond more slowly than children. A response in up to 80-90% has been recorded in adolescents and adults. However, the time to remission is up to 16 weeks. If patients are steroid-resistant or they relapse frequently, a trial of immunosuppressants is given.

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), alone or in combination, should be used with a goal of reducing the proteinuria. Blood pressure and renal function should be monitored closely in patients on ACE inhibitors and ARBs.

The presence of hypovolemia necessitates immediate volume expansion with purified plasma protein fraction and isotonic sodium chloride solution. Parenteral albumin infusions are not appropriate for long-term management of hypoalbuminemia because they have only a transient effect. Such crises should be avoided with recognition of the earlier signs of hypovolemia, including abdominal pain, increase in hematocrit, and response to contributing factors (eg, diarrhea, septicemia, diuretic therapy).

Edema should be controlled by dietary sodium restriction. Small amounts of edema are not of much clinical significance. The use of diuretics should be reserved for patients with severe edema, particularly in the presence of respiratory or gastrointestinal symptoms, and when the condition restricts activity.

Thrombotic episodes should be prevented by mobilization and meticulous attention to venipuncture and intravenous infusion sites. Established episodes should be managed with heparinization.

Infections must be treated aggressively. Cellulitis, peritonitis, otitis, and pneumonia are common infections. Susceptibility to pneumococcal infections warrants the administration of penicillin prophylaxis to patients in relapse. Corticosteroids increase susceptibility to infection.

Diet and Activity

An adequate dietary protein intake, in accordance with the recommended daily allowance (RDA) is necessary. No evidence suggests that hepatic albumin synthesis is elevated with protein intake that is higher than the RDA.

Dietary sodium restriction helps forestall the progression of edema and also is prudent in the management of hypertension.

Mobilization, rather than bed rest, is indicated to avoid thromboembolic complications.

Medication Summary

Pharmacologic treatment in patients with minimal change disease (MCD) includes the use of diuretics to decrease severe edema. Nonsteroidal anti-inflammatory drugs (NSAIDs) also can be used to decrease proteinuria.

Patients usually respond to steroids. The response is defined in terms of proteinuria, as follows:

A typical initial regimen in adults consists of oral prednisone in a daily dosage of 1 mg/kg of body weight for 8-16 weeks (or for 1 wk after remission has been induced). The patient is then placed on an alternate-day single-dose (1 mg/kg) regimen to minimize the incidence of adverse effects. If proteinuria disappears or falls to a very low level, high-dose alternate-day therapy is continued for several weeks to 1 month and prednisone is then slowly tapered over several months in an attempt to reduce the likelihood of relapse.

Patients with steroid-sensitive MCD have complete remission within 8-12 weeks with infrequent relapses. Children usually respond within 4-6 weeks. Adults tend to respond slowly, with more than 25% taking as long as 12-16 weeks to attain complete remission. Treatment usually is continued for another 6 weeks after complete remission of proteinuria occurs.

If remission is followed by recurrence, a second course of steroids is given. Those patients who need steroids repeatedly are categorized as frequent relapsers or steroid dependent. Relapse in these patients can occur either during tapering of steroids or after cessation of therapy. In these patients, cytotoxic drugs (eg, cyclophosphamide, chlorambucil, or cyclosporine) can be considered to either induce a remission or decrease the adverse effects of continuous steroid use.

Cyclophosphamide may be given in a dosage of 2 mg/kg/d for 8-12 weeks. Cyclosporine is given in a dosage of 4-6 mg/kg/d.) also can be used in patients who continue to relapse or who are steroid-dependent. Because cyclophosphamide is less expensive than cyclosporine and has a better response rate, it is preferable to cyclosporine in most patients with steroid-dependent or frequently relapsing MCD.

Mycophenolate mofetil (MMF) may also be beneficial to patients with frequent relapses. This was suggested by a small study where 7 patients with MCD and FSGS with multiple relapses were treated with MMF (1 g bid). After 1 year, 5 of the 7 patients were still in remission, and the steroid dose was significantly decreased. In addition, the immunomodulator levamisole also has been used in children.

Steroid-resistant patients: If no reduction in proteinuria occurs by 12-16 weeks, adults are considered steroid-resistant. The most common cause of this is misdiagnosis. Studies in adults and children have shown that both cyclophosphamide and cyclosporine added to steroid treatment may induce remission.[7] Moreover, if these patients relapse at a later time, they tend to become steroid-sensitive.

Secondary steroid-resistant: Some patients develop secondary steroid resistance after an initial response to steroids.

In children, repeat biopsy can alter the treatment plan in a significant number of patients. Long-term follow-up of patients with MCD persisting post puberty shows that they are at increased risk of osteoporosis, myopia, and hypertension.

In patients who do not respond to treatment, follow-up biopsies have been found to show either IgM nephropathy or FSGS.

A study by Swartz et al of 55 children with steroid-resistant or steroid-dependent MCD determined that 23 of these patients also had mesangial IgM that was visible through immunofluorescence (one of the characteristics of IgM nephropathy).[8] The investigators also found that the children with MCD and immunofluorescently-visible IgM responded better to treatment with cyclosporine than to therapy with cyclophosphamide.

Adults are particularly prone to the adverse effects of corticosteroids, but they do well on cyclophosphamide.

Cyclosporine may be used as an alternative to cyclophosphamide in order to avoid toxicities associated with the latter.[9] Keeping the dosage of cyclosporine at a minimum and carefully monitoring the drug’s levels have been shown to be helpful in avoiding cyclosporine-associated nephrotoxicity.

Rituximab has been shown to be effective against minimal-change disease. Relapse has been linked to the reappearance of B19 cells, which rituximab depletes. Rituximab may therefore have a role in the treatment of steroid-dependent and multirelapsing patients. In one trial with immunosuppressant-dependent young adults, a good response was seen with rituximab. It has been shown to be reasonably well tolerated.[10, 11]

Rituximab has also been shown to be very effective in small trials in adults with steroid resistance.[12]

In 20% of steroid-resistant patients, a genetic mutation may be responsible. One of these is the NPHS2 mutation; however, heterozygotes respond well to steroids.[13] The treatment of MCD with tacrolimus has produced varying results.[14, 15, 16]

The choice of immunosuppressants includes cyclophosphamide and chlorambucil. These drugs expose the patient to a wide range of serious adverse effects that include life-threatening infections, gonadal dysfunction, bone marrow dysfunction, and, in the case of chlorambucil, increased risk of leukemia. Pulse cyclophosphamide failed to adequately suppress recurrence of minimal-change nephrotic syndrome in a small group of children who were steroid-dependent. In children with steroid-resistant nephrotic syndrome, those who received tacrolimus (another calcineurin inhibitor) and steroids had a higher complete/partial remission rate and increased chances of sustained remission with fewer adverse effects compared with those who received cyclophosphamide.[17]

Cyclosporine is considered to be an acceptable drug for maintenance therapy in patients with frequent relapses and steroid dependency. However, it is less efficacious than cyclophosphamide at maintaining sustained remission.

Mycophenolate mofetil (MMF) has been shown in limited studies to be beneficial in patients who are steroid dependent or have frequent remissions. Unfortunately, the evidence for the benefit of this drug is scant at this time, and it should be considered only when patients develop serious adverse effects to steroid treatment and refuse treatment with cyclophosphamide.

Long-term remission with rituximab (an anti-CD20 antibody) in patients who have failed conventional immunosuppressive therapy has been tried with reasonable success and acceptable side effect profile. However, randomized controlled trials need to be conducted before guidelines can be issued.[10, 18, 19]

Furosemide (Lasix)

Clinical Context:  Has potent diuretic effects by blocking the sodium reabsorption in the thick ascending limb of the loop of Henle.

Class Summary

These agents control volume overload.

Prednisone (Sterapred)

Clinical Context:  Exerts anti-inflammatory effect via the inhibition of inflammatory mediator gene transcription.

Class Summary

For remission of proteinuria.

Cyclophosphamide (Cytoxan, Neosar)

Clinical Context:  Interferes with normal function of DNA by alkylation and cross-linking strands of DNA and by possible protein modification.

Class Summary

For remission of nephrotic syndrome.

Cyclosporine A (Sandimmune, Neoral)

Clinical Context:  Inhibits production and release of IL-2, leading to inhibition of IL-2–mediated activation of T lymphocytes.

Chlorambucil (Leukeran)

Clinical Context:  To induce remission of proteinuria. Interferes with DNA replication and RNA transcription.

Class Summary

For remission of nephrotic syndrome.

Levamisole (Ergamisol)

Clinical Context:  Stimulates formation of antibodies and enhances T-cell responses. Acts as a biochemical modulator of fluorouracil.

Mycophenolate mofetil (CellCept)

Clinical Context:  Inhibitor of de novo purine pathway with preferential inhibitory effects on T and B lymphocyte proliferation, has been used to treat steroid-dependent nephrotic syndrome.

Class Summary

To induce remission of nephrotic syndrome.

Further Outpatient Care

MCD is treated in the outpatient setting. Followup care includes the following:

Complications

The most common complications are the adverse effects of medications. Additional complications may include peritonitis, infections, and acute renal failure. Acute renal failure occurs because of either acute tubular necrosis or acute tubulointerstitial nephritis. In a retrospective review of 95 adult patients with MCD, Waldman et al reported that 24 patients had acute renal failure, with these individuals tending to be older and hypertensive, and to have lower serum albumin and more proteinuria than did patients who did not suffer acute renal failure.[20]

Patients with nephrotic syndrome have an increased incidence of arterial and venous thromboemboli, particularly deep vein and renal vein thrombosis. Renal vein thrombosis is known to occur in patients with MCD, although the incidence is lower than in patients with membranous nephropathy.

Hypercholesterolemia and hypertriglyceridemia can lead to accelerated atherosclerosis and perhaps cause progressive glomerular injury.

Prognosis

Use of antibiotics and glucocorticoids and better-organized schedules of management have substantially reduced the mortality rates associated with MCD. Deaths still occur from disease complications.

Relapses eventually cease. Only approximately 5% of children continue to have steroid-responsive relapses when older than 18 years.

Adults have a similarly good prognosis. Survival rates of 85-90% are observed 10 years or more after disease onset.

Chronic renal failure is extremely rare in patients who are steroid responsive. If chronic renal failure occurs, the possibility that the pathologic lesion is different or has evolved must be considered.

Author

Abeera Mansur, MD, Consultant Nephrologist, Doctors Hospital and Medical Center, Pakistan

Disclosure: Nothing to disclose.

Coauthor(s)

Florin Georgescu, MD, Consulting Staff, Kidney Specialists of Savannah

Disclosure: Nothing to disclose.

Susie Lew, MD, Professor of Medicine, Department of Medicine, Division of Renal Diseases and Hypertension, George Washington Unversity School of Medicine and Health Sciences; Medical Director, Peritoneal Dialysis Unit, George Washington University Medical Center, Gambro Healthcare/DaVita

Disclosure: Amgen Grant/research funds investigator; Gambro Consulting fee Consulting; Questcor Grant/research funds investigator; Bristol Meyers Squibb Grant/research funds investigator; CMS Grant/research funds investigator

Specialty Editors

Anil Kumar Mandal, MD, Clinical Professor, Department of Internal Medicine, Division of Nephrology, University of Florida College of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Eleanor Lederer, MD, Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital

Disclosure: Dept of Veterans Affairs Grant/research funds Research; American Society of Nephrology Salary ASN Council Position; University of Louisville Salary Employment; University of Louisville Physicians Salary Employment; American Physician Institute for Advanced Professional Studies, LLC contract payment Independent contractor; Healthcare Quality Strategies, Inc contract payment Independent contractor

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Vecihi Batuman, MD, FACP, FASN, Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Disclosure: Nothing to disclose.

References

  1. Shao YN, Chen YC, Jenq CC, et al. Serum immunoglobulin E can predict minimal change disease before renal biopsy. Am J Med Sci. Oct 2009;338(4):264-7. [View Abstract]
  2. Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol. May 2007;18(5):1476-85. [View Abstract]
  3. Izzedine H, Brocheriou I, Eymard B, et al. Loss of podocyte dysferlin expression is associated with minimal change nephropathy. Am J Kidney Dis. Jul 2006;48(1):143-50. [View Abstract]
  4. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int. Aug 2010;78(3):296-302.
  5. Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, et al. Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol. Feb 2015;30(2):309-16. [View Abstract]
  6. Kontchou LM, Liccioli G, Pela I. Blood pressure in children with minimal change nephrotic syndrome during oedema and after steroid therapy: the influence of familial essential hypertension. Kidney Blood Press Res. 2009;32(4):258-62. [View Abstract]
  7. Hamasaki Y, Yoshikawa N, Hattori S, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. Nov 2009;24(11):2177-85. [View Abstract]
  8. Swartz SJ, Eldin KW, Hicks MJ, Feig DI. Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome. Pediatr Nephrol. Jun 2009;24(6):1187-92. [View Abstract]
  9. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int. Dec 2007;72(12):1429-47. [View Abstract]
  10. Sellier-Leclerc AL, Macher MA, Loirat C, Guerin V, Watier H, Peuchmaur M. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. Jun 2010;25(6):1109-15. [View Abstract]
  11. Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol. Aug 2011;76(2):151-8. [View Abstract]
  12. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. Jan 16 2013;[View Abstract]
  13. Caridi G, Gigante M, Ravani P, et al. Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. Clin J Am Soc Nephrol. Jun 2009;4(6):1065-72. [View Abstract]
  14. Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant. Jun 2008;23(6):1919-25. [View Abstract]
  15. Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. Jul 2006;21(7):1848-54. [View Abstract]
  16. Westhoff TH, Schmidt S, Zidek W, Beige J, van der Giet M. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol. Jun 2006;65(6):393-400. [View Abstract]
  17. Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. Nov 2012;82(10):1130-5. [View Abstract]
  18. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25(3:359.
  19. Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. Nov 2014;29(11):2084-91. [View Abstract]
  20. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. May 2007;2(3):445-53. [View Abstract]
  21. Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron. Apr 2000;84(4):342-6. [View Abstract]
  22. Araya CE, Wasserfall CH, Brusko TM, et al. A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. May 2006;21(5):603-10. [View Abstract]
  23. Audard V, Larousserie F, Grimbert P, et al. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int. Jun 2006;69(12):2251-60. [View Abstract]
  24. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis. Dec 2003;42(6):1114-20. [View Abstract]
  25. Bonilla-Felix M, Parra C, Dajani T, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int. May 1999;55(5):1885-90. [View Abstract]
  26. Cho BS, Yoon SR, Jang JY, Pyun KH, Lee CE. Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change nephrotic syndrome. Pediatr Nephrol. Apr 1999;13(3):199-204. [View Abstract]
  27. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. Mar 2002;61(3):1098-114. [View Abstract]
  28. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. Nov 2002;17(11):2011-3. [View Abstract]
  29. Dijkman HB, Wetzels JF, Gemmink JH, Baede J, Levtchenko EN, Steenbergen EJ. Glomerular involution in children with frequently relapsing minimal change nephrotic syndrome: an unrecognized form of glomerulosclerosis?. Kidney Int. Jan 2007;71(1):44-52. [View Abstract]
  30. Donia AF, Gazareen SH, Ahmed HA, et al. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant. Oct 2003;18(10):2054-8. [View Abstract]
  31. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant. Feb 2003;18(2):245-8. [View Abstract]
  32. Humphreys BD, Vanguri VK, Henderson J, Antin JH. Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient. Nat Clin Pract Nephrol. Sep 2006;2(9):535-9; quiz 540. [View Abstract]
  33. Jennette JC, Falk RJ. Adult minimal change glomerulopathy with acute renal failure. Am J Kidney Dis. Nov 1990;16(5):432-7. [View Abstract]
  34. Kyrieleis HA, Lowik MM, Pronk I, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. Oct 2009;4(10):1593-600. [View Abstract]
  35. Lahdenkari AT, Kestila M, Holmberg C, Koskimies O, Jalanko H. Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). Kidney Int. May 2004;65(5):1856-63. [View Abstract]
  36. Matsumoto K, Kanmatsuse K. Increased IL-12 release by monocytes in nephrotic patients. Clin Exp Immunol. Aug 1999;117(2):361-7. [View Abstract]
  37. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. Mar 2002;39(3):503-12. [View Abstract]
  38. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. Dec 1994;125(6 Pt 1):981-6. [View Abstract]
  39. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. Jun 1986;29(6):1215-23. [View Abstract]
  40. Prasad GV, Vincent L, Hamilton R, Lim K. Minimal change disease in association with fire coral (Millepora species) exposure. Am J Kidney Dis. Jan 2006;47(1):e15-6. [View Abstract]
  41. Smith JD, Hayslett JP. Reversible renal failure in the nephrotic syndrome. Am J Kidney Dis. Mar 1992;19(3):201-13. [View Abstract]
  42. Tang HL, Chu KH, Mak YF, et al. Minimal change disease following exposure to mercury-containing skin lightening cream. Hong Kong Med J. Aug 2006;12(4):316-8. [View Abstract]
  43. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. May 1997;8(5):769-76. [View Abstract]
  44. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. Apr 1981;98(4):561-4. [View Abstract]
  45. Wei CL, Cheung W, Heng CK, et al. Interleukin-13 genetic polymorphisms in Singapore Chinese children correlate with long-term outcome of minimal-change disease. Nephrol Dial Transplant. Apr 2005;20(4):728-34. [View Abstract]